Effect of Glucotrol XL on Glyeaemic Control in Non-insulin Dependent Diabetic Patients

Author: M. Petkova, Diabetes Center, Orthodox Polyclinic „St. Luca" – Sofia

To eveluate the efficacy and safety of Glucotrol XL® on the glyeaemic control in non-insulin dependent diabetic patients (NIDDM) an open, randomized trial was carried out.

Forty thee (21 male and 22 female) NIDDM patients, previously treated with Minidiab with mean age 61,47 ± 9,17 years, duration of diabetes 12,92 ± 3,28 years, BMI 28,2 ± 2,3 kg/m² were included in the study. Statistically significant lower fasting (9,12 ± 2,19 vs. 7,8 ± 2,77 mmol/l, p < 0,05) and 2 hours after standard breakfast blood glucose level (9,77 ± 3,83 vs. 7,9 ± 2,7847 mmol/l, p < 0,05) was found 3 months after treatment with Glucotrol XL® compared with Minidiab treatment.

The glycaemic control, evaluated as HbA_1c was improved with 0,88% after 3 months. BMI did not change (28,2 ± 2,3 kg/m² vs. 27,8 ± 1,4 kg/m²) after 3 months with Glucotrol XL® treatment.

Mean daily dose of Clucotrol XL® was statistically significant lower compared to Minidiab (6,4 ± 2,25 vs. 16,45 ± 7,45 mg).

The results of the present study indicate that Clucotrol XL® is safe and efficient in NIDDM patients.

The minimal dose of Glucotrol XL® given once daily produces significantly lower fasting and postprandial glycaemia and improves the glycaemic control compared to 15 mg Minidiab.

Keywords: NIDDM, Glipizide gastrointestinal therapeutic system, efficacy.

Download the full issue 4/1998